



556 Gibraltar Drive
 Milpitas, CA 95035
 T: (800) 832-3200
 F: (408) 935-8272

www.igenex.com

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914
 CALIFORNIA: CLF 4033
 NPI: 1396837605

REFERRING PHYSICIAN

TEST DOCTOR

TEST PATIENT

DOB:
Gender:
Accession:
Patient ID:

Collected:
 Received:
 Reported:
 Reprinted:
 Amended:
 Corrected:

BORRELIOSIS - Lyme Disease

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS								
Lyme ImmunoBlot IgG IGX Criteria: CDC/NYS Criteria: *** [REVISED REPORT: EFFECTIVE APRIL 10, 2019] Lyme ImmunoBlot IgG detects antibodies to B. burgdorferi strains and species	Serum	Positive Negative										
Band (kDa)	18	23*	28	30	31*	34*	39*	41*	45	58	66	93*
Intensity	-	+	-	-	-	-	-	+	-	-	-	+

Band Intensity: Positive: + to +++++, Indeterminate: Ind, Negative: (-)

INTERPRETATION

Positive

Negative

IGX CRITERIA

2 or more of the starred bands are present (+): 23*, 31*, 34*, 39*, 41*, 93* kDa

Does not meet IGX criteria for a positive.

CDC/NYS CRITERIA

5 or more of the following bands are present (+): 18, 23*, 28, 30, 39*, 41*, 45, 58, 66, 93* kDa

Does not meet CDC/NYS criteria for a positive.

LIMITATION: Bands 31* and 34* kDa are present in Lyme vaccinated patients. Viral antibodies cross react with the 93 kDa antigen.

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.



556 Gibraltar Drive
 Milpitas, CA 95035
 T: (800) 832-3200
 F: (408) 935-8272

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914
 CALIFORNIA: CLF 4033
 NPI: 1396837605

www.igenex.com

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
------	----------	--------	-----------------	-------

LYME IMMUNOBLOT IGG SPECIATION

B. burgdorferi US(genus)	Serum	Positive		
B. burgdorferi US spp	Serum	Negative		


BbSs: Borrelia burgdorferi sensu stricto includes but not limited to B. burgdorferi B31 and B. burgdorferi 29
BbSl: Borrelia burgdorferi sensu lato includes but not limited to B. mayonii and B. californiensis.

B. burgdorferi European(genus)	Serum	Negative		
B. burgdorferi European Spp	Serum	Negative		

Borrelia burgdorferi European species include but not limited to B. afzelii, B. garinii, B. spielmanii and B. valaisiana.

B. burgdorferi Species	Serum	Positive		
------------------------	-------	----------	--	--

B. burgdorferi species include but not limited to Bb B31, Bb 297, mayonii, B. californiensis, B. afzelii, B. garinii, B. spielmanii and B. valaisian



Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.



556 Gibraltar Drive
 Milpitas, CA 95035
 T: (800) 832-3200
 F: (408) 935-8272

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914
 CALIFORNIA: CLF 4033
 NPI: 1396837605

www.igenex.com

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
------	----------	--------	-----------------	-------

Lyme ImmunoBlot IgM	Serum	Positive		
IGX Criteria:		Positive		
CDC/NYS Criteria:		Positive		

 [REVISED REPORT: EFFECTIVE APRIL 10, 2019]

Lyme ImmunoBlot IgM detects antibodies to B. burgdorferi strains and species

Band (kDa)	31*	34*	39*	41*	93
Intensity	+	+	-	+	IND

Band Intensity: Positive: + to +++++, Indeterminate: Ind, Negative: (-)

INTERPRETATION	IGX CRITERIA	CDC/NYS CRITERIA
Positive	2 or more of the starred bands are present (+): 23*, 31*, 34*, 39*, 41* kDa	2 or more of the following bands are present (+): 23*, 39*, 41* kDa
Negative	Does not meet IGX criteria for a positive.	Does not meet CDC/NYS criteria for a positive.

LIMITATION: Bands 31* and 34* kDa are present in Lyme vaccinated patients. Viral antibodies cross react with the 93 kDa antigen.

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.



556 Gibraltar Drive
 Milpitas, CA 95035
 T: (800) 832-3200
 F: (408) 935-8272

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914
 CALIFORNIA: CLF 4033
 NPI: 1396837605

www.igenex.com

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
------	----------	--------	-----------------	-------

LYME IMMUNOBLOT IGM SPECIATION

B. burgdorferi US(genus)	Serum	Positive		
B. burgdorferi US Spp	Serum	Negative		

BbSs: Borrelia burgdorferi sensu stricto includes but not limited to B. burgdorferi B31 and B. burgdorferi 29
BbSl: Borrelia burgdorferi sensu lato includes but not limited to B. mayonii and B. californiensis.

B. burgdorferi European(genus)	Serum	Positive		
B. burgdorferi European Spp	Serum	Negative		

Borrelia burgdorferi European species include but not limited to B. afzelii, B. garinii, B. spielmanii and B. valaisiana.

B. burgdorferi Species	Serum	Positive		
------------------------	-------	----------	--	--

B. burgdorferi species include but not limited to Bb B31, Bb 297, mayonii, B. californiensis, B. afzelii, B. garinii, B. spielmanii and B. valaisian

Lyme Serology IgG/IgM	Serum	0.71	Negative: <1.0 Equivocal: 1.0 - <1.2 Positive: >or= 1.2	LIV
-----------------------	-------	------	---	-----

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.



556 Gibraltar Drive
 Milpitas, CA 95035
 T: (800) 832-3200
 F: (408) 935-8272

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914
 CALIFORNIA: CLF 4033
 NPI: 1396837605

www.igenex.com

BORRELIOSIS- Relapsing Fever Borrelia

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
TBRF Borrelia ImmunoBlot IgG		IND	Positive:	Detected 2 or more TBRF Borrelia species-specific antibodies.
TBRF Borrelia genus ImmunoBlot IgG Serum			Indeterminate:	Detected only 1 TBRF Borrelia species-specific antibody.
			Negative:	No TBRF Borrelia specific antibody detected.

* TBRF ImmunoBlot IgG detects antibodies to *Borrelia hermsii*, *B. turicatae*, *B. miyamotoi*, *B. coriciae* and TBRF Borrelia species.

TBRF Borrelia ImmunoBlot IgG Species	SPECIMEN	RESULT
<i>B. miyamotoi</i>	Serum	Negative
<i>B. hermsii</i>	Serum	Negative
<i>B. turicatae</i>	Serum	Negative
TBRF Borrelia spp	Serum	Negative

TBRF Borrelia ImmunoBlot IgM	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
TBRF Borrelia genus ImmunoBlot IgM Serum		IND	Positive:	Detected 2 or more TBRF Borrelia species-specific antibodies.
			Indeterminate:	Detected species-specific antibody.
			Negative:	No TBRF Borrelia specific antibody detected.

* TBRF ImmunoBlot IgM detects antibodies to *Borrelia hermsii*, *B. turicatae*, *B. miyamotoi*, *B. coriciae* and TBRF Borrelia species.

TBRF Borrelia ImmunoBlot IgM Species	SPECIMEN	RESULT
<i>B. miyamotoi</i>	Serum	Negative
<i>B. hermsii</i>	Serum	Negative
<i>B. turicatae</i>	Serum	Negative
TBRF Borrelia spp	Serum	Negative

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.


NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, *C. pneumoniae* IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.

BABESIOSIS

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
B. microti IFA - IgM	Serum	<20	< 20 : Negative = 20 : May or may not indicate active infection >=40 : Indicates active infection	Titer
B. microti IFA - IgG	Serum	<40	< 40 : Negative < 160 : May or may not suggest active infection >=160 : Indicates active infection	Titer

Babesia FISH

W blood Negative



Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.



556 Gibraltar Drive
Milpitas, CA 95035
T: (800) 832-3200
F: (408) 935-8272

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914
CALIFORNIA: CLF 4033
NPI: 1396837605

www.igenex.com

ANAPLASMOSIS

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
HGA IFA - IgM	Serum	<20	< 20 : Negative = 20 : May or may not indicate active infection >=40 : Indicates active infection	Titer
HGA IFA - IgG	Serum	<40	< 40 : Negative < 160 : May or may not suggest active infection >=160 : Indicates active infection	Titer

EHRlichiosis

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
HME IFA - IgM	Serum	<20	< 20 : Negative = 20 : May or may not indicate active infection >=40 : Indicates active infection	Titer
HME IFA - IgG	Serum	<40	< 40 : Negative < 160 : May or may not suggest active infection >=160 : Indicates active infection	Titer

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.



556 Gibraltar Drive
 Milpitas, CA 95035
 T: (800) 832-3200
 F: (408) 935-8272

www.igenex.com

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914
 CALIFORNIA: CLF 4033
 NPI: 1396837605

RICKETTSIOSIS

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
R. rickettsii IFA - IgG	Serum	<40	< 40 : Negative < 160 : May or may not suggest active infection ≥160 : Indicates active infection	Titer
R. typhi IFA - IgG	Serum	<40	< 40 : Negative < 160 : May or may not suggest active infection ≥160 : Indicates active infection	Titer

BARTONELLOSIS

B henselae IFA - IgM	Serum	<20	< 20 : Negative = 20 : May or may not indicate active infection ≥40 : Indicates active infection	Titer
B henselae IFA - IgG	Serum	40	< 40 : Negative < 160 : May or may not suggest active infection ≥160 : Indicates active infection	Titer

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.